Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lutetium (177Lu) DGUL
Lutetium DGUL · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Monotherapy Arm | EXPERIMENTAL | Monotherapy Arm: 10 patients will receive Lutetium (177Lu) DGUL monotherapy. |
| Combination Arm | EXPERIMENTAL | Combination Arm: 20 patients will receive Lutetium (177Lu) DGUL in combination with pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| Lutetium (177Lu) DGUL | DRUG | Lutetium (177Lu) DGUL will be administered in 4 doses at 6-week intervals (Q6W), and for patients showing good tolerance, additional 2 doses may be added, for a maximum of 6 doses. |
| Pembrolizumab | DRUG | Pembrolizumab will be introduced at a dose of 400 mg every 6 weeks, beginning with the second cycle of Lutetium (177Lu) DGUL, and will continue for up to approximately 2 years (18 doses). |
Inclusion Criteria: * Male patients aged 19 years or older. * Patients with histopathologically or cytologically confirmed adenocarcinoma of the prostate, without neuroendocrine or small cell differentiation, who have metastatic disease documented by bone lesions/soft tissue lesions and are not eli...
Lutetium DGUL is an investigational small molecule being studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a radioligand therapy that delivers radiation to cancer cells. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Lutetium DGUL is a radioligand therapy that uses the radioactive isotope lutetium-177. While the specific molecular target is not disclosed, the drug is designed to bind to prostate cancer cells and deliver targeted radiation. It is being evaluated in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer.
Lutetium DGUL is being developed by Merck & Company, Inc., a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with metastatic castration-resistant prostate cancer.
Lutetium DGUL is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of the drug in combination with pembrolizumab.
Lutetium DGUL is being studied in a Phase 1 clinical trial with the identifier NCT07244393. The trial, titled 'Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer,' is not yet recruiting and aims to enroll 30 male patients aged 19 years and older.
Yes, Lutetium DGUL is also known as Lutetium (177Lu) DGUL. The alternative name specifies the radioactive isotope lutetium-177 used in the drug's composition. Both names refer to the same investigational compound being developed by Merck for metastatic castration-resistant prostate cancer.